Home - Ayala Pharmaceuticals

Time 2022-10-01 07:12:58

Web Name: Home - Ayala Pharmaceuticals

WebSite: http://www.ayalapharma.com

ID:335890

Keywords:

Home,Ayala,Pharmaceuticals

Description:

Contact UsCareers

WHO WE ARE OUR MISSIONMEET OUR TEAM PIPELINE OUR APPROACHGAMMA SECRETASE INHIBITORS (GSIs)INVESTIGATIONAL THERAPIES: AL101 & AL102 CLINICAL TRIALS CLINICAL PRIVACY NOTICEMEDICAL PROFESSIONALS PATIENTS & CAREGIVERS SCIENCE EXPLAINEDPARTICIPATING IN CLINICAL TRIALSEXPANDED ACCESS POLICYPATIENT RESOURCES INVESTORS & MEDIA NEWS RELEASESEVENTS & PRESENTATIONSFINANCIAL INFORMATIONSTOCK INFORMATIONCORPORATE GOVERNANCERESOURCESPARTNERS

Who We Are Our MissionMeet Our TeamPipeline Our ApproachGamma Secretase Inhibitors (GSI)INVESTIGATIONAL THERAPIES: AL101 & AL102Clinical Trials Clinical Privacy NoticeMedical ProfessionalsPatients and Caregivers Science ExplainedParticipating in Clinical TrialsExpanded Access PolicyPatient ResourcesInvestors & Media NEWS RELEASESEVENTS & PRESENTATIONSFINANCIAL INFORMATIONSTOCK INFORMATIONCORPORATE GOVERNANCERESOURCESPartnersCareersContact Us ×

We aim to transform lives

Compassion, integrity and efficiency are at the center of everything we do to impact the lives of people living with rare cancers.

Our Approach

SCROLL

OUR PROMISE

Science Driven by People

We focus on the cure

At Ayala, we are dedicated to developing targeted therapies specifically for patients living with rare and aggressive diseases. In combination with next-generation sequencing and our proprietary bioinformatics platform, we are pioneering a novel approach to cancer treatment.

Who We AreRoni Mamluk, Ph.D., Founder and Chief Executive Officer, Ayala Pharmaceuticals

“People living with rare and aggressive cancers have an enormous unmet need. We are working to bring a new treatment option to market that can make a true difference in the lives of these individuals and their families.”

The Science Behind Our Drugs

We develop gamma secretase inhibitors to treat cancer. Put in simple terms, it’s a way to disrupt tumor growth and metastatic spread by targeting the activation of the Notch pathway. Gamma secretase is the enzyme responsible for Notch activation, and when inhibited, turns off Notch pathway activation.

Learn More

The Notch pathway is involved in embryonic development and in the renewal and maintenance of adult tissues. In cancers, Notch is known to serve as a critical facilitator in processes such as cellular proliferation, survival, migration, invasion, drug resistance and metastatic spread, all of which contribute to tumorigenesis and cancer progression. Inhibition of Notch by γ-secretase inhibitors (GSIs) such as AL101/AL102 turns off Notch pathway activation.

Latest News

September 29, 2022

Ayala Pharmaceuticals to Host Key Opinion Leader Webinar on Desmoid Tumors

September 27, 2022

Ayala Pharmaceuticals Announces Fast Track Designation Granted by US FDA for AL102 in Progressing Desmoid Tumors

September 12, 2022

Ayala Pharmaceuticals Presents Positive Interim Data from RINGSIDE Pivotal Phase 2/3 Trial of AL102 in Desmoid Tumors at ESMO Congress 2022

Read More

TAGS:Home Ayala Pharmaceuticals

<<< Thank you for your visit >>>

Hot Websites